Esperion
Company

Last deal

$85.1M

Amount

Post-IPO Equity

Stage

18.01.2024

Date

3

all rounds

$849.25M

Total amount

date founded

Financing round

General

About Company
Esperion is a pharmaceutical company that develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Esperion Therapeutics

founded date

01.01.1998

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company specializes in researching, developing, and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. Esperion's unique approach, called "HDL Therapy," focuses on the function of high-density lipoprotein, or HDL, to develop a novel class of drugs. The company's goal is to make lipid management accessible to everyone by discovering, developing, and commercializing innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren't being met by current treatments. Esperion's team of industry leaders is inclusive, passionate, and resourceful.
Contacts

Phone number

Social url

Similar Companies
1000
Newron Pharmaceuticals

Newron Pharmaceuticals

Newron Pharmaceuticals is developing novel therapies for diseases of the central nervous system and pain.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

20091 Bresso, Metropolitan City of Milan, Italy

total rounds

10

total raised

$129.43M
Ascent Therapeutics

Ascent Therapeutics

Ascent Therapeutics develops pepducins, a new class of drugs targeting G-protein coupled receptors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

1

total raised

$19M
Lewis and Clark Pharmaceuticals

Lewis and Clark Pharmaceuticals

Lewis and Clark Pharmaceuticals develops potent treatments for cancer and inflammatory diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Charlottesville, VA, USA

total rounds

2

total raised

$475K
Zogenix

Zogenix

Zogenix develops and commercializes differentiated CNS and pain therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Pharmaceuticals

Location

San Diego, CA, USA

total rounds

14

total raised

$1.45B
M&A Details
1

Transaction name

Acquired by

Pfizer

announced date

21.12.2003

price

$1.3B

Financials

Funding Rounds
8
3

Number of Funding Rounds

$849.25M

Money Raised

Their latest funding was raised on 18.01.2024. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
18.01.2024
$85.1M
02.12.2021
$225M
Oberland Capital

Oberland Capital

Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Wealth Management, Finance

Location

New York, NY, USA

count Of Investments

11

count Of Exists

3
Co-Investors
Investors
7
6

Number of lead investors

7

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Equity
Yes
Series A, Venture - Series Unknown
Yes
Series A, Venture - Series Unknown
Oberland Capital

Oberland Capital

Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Wealth Management, Finance

Location

New York, NY, USA

count Of Investments

11

count Of Exists

3
Aisling Capital

Aisling Capital

Aisling Capital is a venture capital firm based in New York that focuses on investing in the pharmaceutical and biotechnology sectors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Venture Capital, Financial Services

Location

New York, NY, USA

count Of Investments

104

count Of Exists

27
Dov Goldstein

Dov Goldstein

Dov joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the company’s growth strategies as well as operational finance and business development. Previously, Dov was CEO at RIGImmune from 2018 to 2020, CFO of Schrödinger from 2017 to 2018, and a partner at Aisling Capital from 2006 to 2017. From 2014 to 2015, he served as the CFO of Loxo Oncology, which was later acquired by Lilly for $8 billion. From 2000 to 2005, Dov served as CFO of Vicuron Pharmaceuticals (acquired by Pfizer in 2005 for $1.9 billion), where he raised over $250 million in equity financing and played major roles in the company’s partnership transactions. Dov currently serves on the board of directors of Gain Therapeutics, Neubase Therapeutics, and Coya Therapeutics, and previously held seats on the boards of, ADMA Biologics, Cempra Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, and Loxo Oncology. Dov has an MD from Yale School of Medicine, an MBA from Columbia Business School, and a BS in Biological Sciences from Stanford University.

current job

BIOAGE LABS
BIOAGE LABS
Domain Associates

Domain Associates

Domain Associates is a venture capital firm that invests exclusively in life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

San Diego, CA, USA

count Of Investments

241

count Of Exists

65
Nicole Vitullo

Nicole Vitullo

Nicole Vitullo joined Domain Associates, L.L.C. in 1999 and became a Partner in 2004. She has full management responsibility for Domain Public Equity Partners, L.P. and is also involved in distribution/liquidation strategies for the public companies in Domain Associate’s venture capital portfolios. Present board memberships include Celator Pharmaceuticals, Inc.; Cerexa, Inc.; Ruxton Pharmaceuticals; and Marinus Pharmaceuticals. Past Board memberships include Onyx Pharmaceuticals and Eunoe, Inc. From 1992-1999, Ms. Vitullo was Senior Vice President at Rothschild Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust plc and Biotechnology Investments Limited. From 1991-1992, Ms. Vitullo served as the Director of Corporation Communications and Investor Relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Ms. Vitullo spent 12 years at Eastman Kodak, most recently in Corporation Development where she was involved in the development management of Kodak’s venture capital activities. Ms. Vitullo has a B.A. and an M.B.A. from the University of Rochester.

current job

Domain Associates
Domain Associates

People

Founders
1
Roger S. Newton
Roger S. Newton

Roger S. Newton

Roger Newton is the Sr. VP and Director at Esperion Therapeutics.

current job

Esperion
Esperion

Roger S. Newton

Employee Profiles
57

Brittany Baratz

Senior travel and expense specialist

Laurie Danison

Senior manager, collaboration and web services

Hemant Mistry

Executive director, head of program management

Benjamin Church

Head of corporate communications and investor relations

Ottavio Bagnardi

Regional sales manager

Christian Schell

Manager, cgmp quality systems - drug product

Don Sewell

Regional sales manager

Jeff Vengley

National sales director

Activity

Recent News
3
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week